Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.
Additional trials of targeted therapies, including the use of granulocyte colony-stimulating factors (G-CSF), are needed to optimize pegfilgrastim use in clinical practices, according to a new study.
Chemotherapy-induced febrile neutropenia (FN), a side effect of cancer treatment, can potentially result in fatal consequences. Guidelines currently exist that recommend the use of G-CSF for preventing FN; however, the guidance does not extend to short- and long-acting G-CSF. A paper published in Supportive Cancer Care develops additional guidance recommendations following a literature review, survey, evaluation of current practice, and a meeting of experts.
“In November 2015, a group of experts in the management of chemotherapy-induced FN, with experience in solid tumors and hematologic malignancies, convened to develop a consensus document to direct the appropriate use of pegfilgrastim in clinical practice,” the authors explained. “The aim was to establish clear guidance recommendations on the appropriate use of pegfilgrastim for prevention of chemotherapy-induced FN, considering different situations and patient populations encountered in clinical practice.”
The main statements and recommendations of the experts included:
The authors did note that the recommendations should be used as a guide along with current guidelines and are not absolute recommendations.
“The expert panel suggests that the guidance statements in this publication should be used in parallel with existing guidelines to optimize the appropriate use of G-CSF and of pegfilgrastim in cancer patients in clinical practice,” the authors concluded.
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More